Companies Dominating the Antiviral Drugs Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The international antiviral drugs market is efficiently consolidated with the existence of key players, including Merck, GSK, and Gilead, collectively dominating with a 51% combined share. These organizations have successfully implemented certain strategies, such as the focus on progression, governmental partnerships, cost-effective accessibility, along with diversification in research and development activities. For instance, the 2024 WHO report demonstrated that generics in India, such as Hetero and Cipla, have supplied 65% of Africa’s HIV drugs at USD 15 per month. Meanwhile, in 2024, Merck’s molnupiravir EU stockpile deals achieved USD 2.5 billion in sales, thereby creating a boost in the overall market.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Industry Focus |
Market Share (2024) |
|
Gilead Sciences (U.S.) |
HIV/HCV therapies (Biktarvy, Sovaldi), COVID-19 antivirals (Veklury) |
26% |
|
GlaxoSmithKline (UK) |
HIV treatments (Dolutegravir), RSV/flu antivirals |
18% |
|
Merck & Co. (U.S.) |
HPV vaccines, molnupiravir (COVID-19), HIV therapies (Isentress) |
15% |
|
Pfizer (U.S.) |
COVID-19 oral antivirals (Paxlovid), RSV/flu therapies |
12% |
|
Roche (Switzerland) |
Tamiflu (oseltamivir), HIV/HCV diagnostics and therapeutics |
9.5% |
|
AbbVie (U.S.) |
HCV treatments (Mavyret), HIV therapies |
xx% |
|
Novartis (Switzerland) |
Broad-spectrum antivirals, pediatric formulations |
xx% |
|
AstraZeneca (UK) |
Long-acting antibody therapies, RSV/COVID-19 combos |
xx% |
|
Johnson & Johnson (U.S.) |
HIV vaccine development, hepatitis B therapies |
xx% |
|
Bristol-Myers Squibb (U.S.) |
HCV/HIV treatments (Daklinza), immunomodulatory antivirals |
xx% |
|
Sanofi (France) |
Influenza vaccines, RSV monoclonal antibodies |
xx% |
|
ViiV Healthcare (UK) |
HIV-focused (Cabenuva, long-acting injectables) |
xx% |
|
Cipla (India) |
Affordable HIV/HCV generics, global supply to LMICs |
xx% |
|
Hetero Drugs (India) |
Largest producer of generic antivirals (remdesivir, acyclovir) |
xx% |
|
Biogen (U.S.) |
Neurological antiviral therapies, mRNA-based R&D |
xx% |
Below are the areas covered for each company in the antiviral drugs market:
